UG

United Guardian is a rare thing: a genuinely high-quality micro-cap trading at a low multiple. The balance sheet is pristine — $1.88M total liabilities against $11.2M equity (0.17x), no debt, the 50,000 sq ft Hauppauge facility owned free and unencumbered, and current assets of $12.2M covering current liabilities 7x over. Profitability is real and structural: 21.3% operating margin, 20.0% net margin, and 18.7% ROE even in a down year. At $7.26 the stock trades at 7.2x FY-diluted EPS and 3.2x sales, and the ~$2.77M dividend (roughly a 8%+ payout on the $33.4M cap, funded by $1.97M operating cash flow plus reserves) pays you to wait. This is not a company at risk of going away.

The problem is the top line, and it is not a one-off. Revenue has gone $13.9M → $12.7M → $10.9M → $12.2M → $10.5M over FY2021-2025 — a choppy but unmistakable downtrend, with FY2025 down 13.4% and net income down 35.2% to $2.11M. Operating income fell 38.5% and operating cash flow fell 43.3%. For a business with high fixed costs (a manufacturing plant, a lab), that operating deleverage cuts both ways: the margin is holding for now, but continued volume erosion will eventually compress it. The MD&A's tell is stark — 'there were no sales of sexual wellness products during 2025' — meaning a product line management is counting on for growth contributed literally nothing last year.